The failure to remyelinate neurons following an attack is one of the major characteristics of multiple sclerosis (MS) ultimately causing the progressive loss of neurological dysfunction.
HER2 is a receptor tyrosine kinase and well-established oncogenic driver with mutations present in various types of tumors such as bladder urothelial carcinoma, uterine corpus endometrial carcinoma, stomach adenocarcinoma and breast cancer.
The Undiagnosed Diseases Network uncovered three unrelated individuals with mutations in the gene encoding serine palmitoyltransferase small subunit A (SPTSSA).
Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors.
Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
RSS
